​

NextCure (NXTC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

NXTC Stock Forecast

NextCure stock forecast is as follows: an average price target of $3.00 (represents a 209.28% upside from NXTC’s last price of $0.97) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

NXTC Price Target

The average price target for NextCure (NXTC) is $3.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 209.28% upside from NXTC's last price of $0.97.

NXTC Analyst Ratings

Buy

According to 1 Wall Street analysts, NextCure's rating consensus is 'Buy'. The analyst rating breakdown for NXTC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

NextCure Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 03, 2024Edward TenthoffPiper Sandler$3.00$1.5297.37%209.28%
Nov 03, 2022Edward TenthoffPiper Sandler$6.00$2.51139.04%518.56%

The latest NextCure stock forecast, released on Jun 03, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $3.00, which represents a 97.37% increase from the stock price at the time of the forecast ($1.52), and a 209.28% increase from NXTC last price ($0.97).

NextCure Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$3.00
Last Closing Price$0.97$0.97$0.97
Upside/Downside-100.00%-100.00%209.28%

In the current month, the average price target of NextCure stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NextCure's last price of $0.97. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jun 03, 2024Piper SandlerOverweightOverweightHold
Nov 03, 2022Piper SandlerOverweightOverweightHold

NextCure's last stock rating was published by Piper Sandler on Jun 03, 2024. The company gave NXTC a "Overweight" rating, the same as its previous rate.

NextCure Financial Forecast

NextCure Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 20Dec 19Sep 19Jun 19
Revenue-------$22.38M$2.00M$1.58M$1.40M
Avg Forecast-------$6.57M$534.17K$3.44M$2.61M
High Forecast-------$6.57M$534.17K$3.44M$2.61M
Low Forecast-------$6.57M$534.17K$3.44M$2.61M
# Analysts-------1111
Surprise %-------3.41%3.75%0.46%0.54%

NextCure's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. NXTC's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $22.38M (Mar 20).

NextCure EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 20Dec 19Sep 19Jun 19
# Analysts-------1111
EBITDA-------$10.48M$-10.17M$-7.65M$-7.64M
Avg Forecast-------$1.31M$106.83K$688.10K$-5.15M
High Forecast-------$1.31M$106.83K$688.10K$-4.12M
Low Forecast-------$1.31M$106.83K$688.10K$-6.18M
Surprise %-------7.98%-95.21%-11.11%1.48%

0 analysts predict NXTC's average Quarter EBITDA for Jun 24 to be -, with a high of - and a low of -. This is -100.00% lower than NextCure's previous annual EBITDA (Mar 20) of $10.48M.

NextCure Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 20Dec 19Sep 19Jun 19
# Analysts-------1111
Net Income-------$9.73M$-10.93M$-8.43M$-8.22M
Avg Forecast$-10.35M$-9.79M$-10.21M$-10.35M$-9.88M$-9.65M$-10.54M$24.09M$-12.71M$-9.79M$-5.54M
High Forecast$-10.35M$-9.79M$-10.21M$-10.35M$-9.01M$-9.65M$-10.54M$28.91M$-12.71M$-9.79M$-4.43M
Low Forecast$-10.35M$-9.79M$-10.21M$-10.35M$-10.47M$-9.65M$-10.54M$19.27M$-12.71M$-9.79M$-6.65M
Surprise %-------0.40%0.86%0.86%1.48%

NextCure's average Quarter net income forecast for Jun 24 is $-10.54M, with a range of $-10.54M to $-10.54M. NXTC's average Quarter net income forecast represents a -208.26% decrease compared to the company's last Quarter net income of $9.73M (Mar 20).

NextCure SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 20Dec 19Sep 19Jun 19
# Analysts-------1111
SG&A-------$3.59M$2.62M$2.62M$2.71M
Avg Forecast-------$6.93M$563.70K$3.63M$1.83M
High Forecast-------$6.93M$563.70K$3.63M$2.19M
Low Forecast-------$6.93M$563.70K$3.63M$1.46M
Surprise %-------0.52%4.64%0.72%1.48%

NextCure's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to NXTC last annual SG&A of $3.59M (Mar 20).

NextCure EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 20Dec 19Sep 19Jun 19
# Analysts-------1111
EPS-------$0.35$-0.40$-0.37$-0.61
Avg Forecast$-0.37$-0.35$-0.36$-0.37$-0.35$-0.34$-0.38$-0.44$-0.45$-0.35$-0.47
High Forecast$-0.37$-0.35$-0.36$-0.37$-0.32$-0.34$-0.38$-0.44$-0.45$-0.35$-0.47
Low Forecast$-0.37$-0.35$-0.36$-0.37$-0.37$-0.34$-0.38$-0.44$-0.45$-0.35$-0.47
Surprise %--------0.79%0.87%1.06%1.31%

According to 0 Wall Street analysts, NextCure's projected average Quarter EPS for Jun 24 is $-0.38, with a low estimate of $-0.38 and a high estimate of $-0.38. This represents a -207.62% decrease compared to NXTC previous annual EPS of $0.35 (Mar 20).

NextCure Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SPROSpero Therapeutics$1.04$10.00861.54%Buy
TILInstil Bio$21.69$150.00591.56%Hold
NXTCNextCure$0.90$3.00233.33%Buy
CTMXCytomX Therapeutics$1.13$3.47207.08%Buy
NUVBNuvation Bio$2.81$7.00149.11%Buy
ASMBAssembly Biosciences$14.28$35.50148.60%Buy
ACHLAchilles Therapeutics$0.97$2.00106.19%Buy

NXTC Forecast FAQ

Is NextCure a good buy?

Yes, according to 1 Wall Street analysts, NextCure (NXTC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of NXTC's total ratings.

What is NXTC's price target?

NextCure (NXTC) average price target is $3 with a range of $3 to $3, implying a 209.28% from its last price of $0.97. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will NextCure stock go up soon?

According to Wall Street analysts' prediction for NXTC stock, the company can go up by 209.28% (from the last price of $0.97 to the average price target of $3), up by 209.28% based on the highest stock price target, and up by 209.28% based on the lowest stock price target.

Can NextCure stock reach $1?

NXTC's average twelve months analyst stock price target of $3 supports the claim that NextCure can reach $1 in the near future.

What are NextCure's analysts' financial forecasts?

NextCure's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.073M (high $-29.201M, low $-30.654M), average SG&A $0 (high $0, low $0), and average EPS is $-1.075 (high $-1.044, low $-1.096). NXTC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-40.705M (high $-40.705M, low $-40.705M), average SG&A $0 (high $0, low $0), and average EPS is $-1.455 (high $-1.455, low $-1.455).

Did the NXTC's actual financial results beat the analysts' financial forecasts?

Based on NextCure's last annual report (Dec 2019), the company's revenue was $6.35M, which missed the average analysts forecast of $6.58M by -3.57%. Apple's EBITDA was $-34.794M, beating the average prediction of $-4.353M by 699.29%. The company's net income was $-29.992M, beating the average estimation of $-28.038M by 6.97%. Apple's SG&A was $9.61M, beating the average forecast of $6.02M by 59.59%. Lastly, the company's EPS was $-1.91, beating the average prediction of $-1.269 by 50.48%. In terms of the last quarterly report (Mar 2020), NextCure's revenue was $22.38M, beating the average analysts' forecast of $6.57M by 240.63%. The company's EBITDA was $10.48M, beating the average prediction of $1.31M by 697.93%. NextCure's net income was $9.73M, missing the average estimation of $24.09M by -59.60%. The company's SG&A was $3.59M, missing the average forecast of $6.93M by -48.25%. Lastly, the company's EPS was $0.35, missing the average prediction of $-0.443 by -179.03%